Leidos : Daiichi Sankyo Becomes the First Pharmaceutical Company to Join OnPAR

Reston, VA., [April 6, 2017] - Leidos welcomes Daiichi Sankyo (DS) to OnPAR, the Online Partnership to Accelerate Research. OnPAR, originally launched by the Leidos Life Sciences team in March 2016, is a partnership with the National Institutes of Health (NIH). It offers a new funding paradigm with the goal of matching highly scored, unfunded applications with potential non-government organizations.

OnPAR is currently expanding nationally and internationally to include other funding agencies. DS, a global pharmaceutical company based in Japan, provides innovative products and services to more than 20 countries around the world. With more than 100 years of scientific expertise, DS has developed a robust pipeline of promising new medicines addressing diverse medical needs with a mission of enriching the quality of life around the world. Daiichi Sankyo's mission and vision aligns with OnPAR's goal to improve global healthcare.

The OnPAR public-private partnership provides a second opportunity for promising, unfunded NIH research proposals. High-quality, high-scoring research applications that were originally submitted to NIH (and soon other funding agencies) and are not funded will be matched for potential funding with a participating organization member's specialized area of interest.

'We welcome Daichii Sankyo to OnPAR,' says Martin Dueñas, Director, Health Research Management Practice, Leidos Life Sciences. 'OnPAR seeks to accelerate research discovery to improve lives for people around the world by providing research investigators a second opportunity for funding without re-writing a new application.'

In addition, OnPAR with Dimensions (in partnership with ÜberResearch) will provide a global research knowledge management platform that will empower funding organizations and private industry to make more informed strategic investments. ÜberResearch now contributes key capabilities from its Dimensions platform to provide global funding landscape data next to the OnPAR grant applications, and its unique natural language processing matching tool to route relevant grant applications to funders.

DS is working to create innovative products that focus on unmet medical needs, specifically in priority therapeutic areas of cardiovascular-metabolics and oncology, to enhance the lives of millions of people around the world. Through OnPAR, DS will review relevant unfunded applications covering the landscape of research from early discovery to translational and clinical projects.

Any funding organization interested in becoming a member can find more information on the OnPAR website at https://onpar.leidosweb.com. Leidos anticipates that both new partners and members will be joining soon. Please visit OnPAR frequently for further announcements and join us in our effort to accelerate research and find cures and treatments for the many diseases affecting our communities.

About Leidos
Leidos is a global science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a 'Global Pharma Innovator with Competitive Advantage in Oncology,' Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

Rashi Ratan
571.526.7781
Rashi.ratan@leidos.com